Larvol Delta - MOAT-A-Study-of-NG641-and-Pembrolizumab-in-Squamous-Cell-Carcinoma-of-the-Head-and-Neck

NG-641 - PsiOxus

Keytruda (pembrolizumab) - Merck (MSD)

http://clinicaltrials.gov/ct2/show/NCT04830592

Jun 29, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next